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Preventing Medication Errors
A medication error is defined by the National Coordinating Council for Medication Error Reporting and
Prevention (NCC MERP), as: “Any preventable event that may cause or lead to inappropriate medication
use or patient harm while the medication is in control of the health care professional, patient or consumer.
Such events may be related to professional practice, health care products, procedures and systems,
including prescribing; order communication; product labelling; packaging and nomenclature;
compounding; dispensing; distribution; administration; education; monitoring or use.”
The health care literature is full of closely related terms that warrant definition as well.
Adverse Drug Event (ADE): An injury resulting from a medication or lack of an intended medication.
Adverse Drug Reaction (ADR): Any unexpected, unintended, undesired or excessive response to a
drug, with or without an injury.
Medication Misadventure: A collective term for events including medication error, ADRs and ADEs.

Commonly Reported Types of Medication Errors:
Prescribing error
Wrong-time error
Unauthorised drug error
Improper dose error
Wrong dosage-form error
Wrong drug preparation error

Omission error
Wrong administration error
Deteriorated drug error
Monitoring error
Compliance error/counselling error

NCC MERP Recommendations to Correct Prescribing Errors
!
!
!
!

All prescription documents should be legible;
Where ever possible, prescription orders should include brief notation of purpose (e.g. for cough);
All prescriptions should be written using the metric system, except for therapies that use standard
units like insulin, vitamins, etc.;
Abbreviations should not be used. Some dangerous abbreviations are: U, Q.D., SC, D/C, Q.O.D. etc.;
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Vague instructions like “use as directed” or “as needed” should be avoided;
Patient’s age and weight should be mentioned on prescription, especially for paediatrics and
geriatrics;
A leading zero or trailing zero can cause tenfold errors in drug strength and dosage. Use them
correctly.

Preventing Dispensing/Compounding Errors:
In order to prevent an error from happening, it is recommended that unnecessary conversation should
not be permitted during:
! Reviewing and assessing the prescription;
! Entering computer data;
! Reviewing patient profile;
! Assessing computer alerts;
! Selecting the proper medication (both in the computer and from the shelf);
! Verifying the product expiration date;
! Counting or measuring the medication;
! Affixing the label;
! Double-checking the prescription;
! Returning the stock container to its original location;
! Taking the patient’s history or counselling the patients.
Other contributing factors like workload, staffing and environmental issues should be identified and
resolved.
E.g. to overcome the dispensing errors, insufficient staffing and lack of time for adequate patient
counselling in community pharmacy, the Iowa State Board of Pharmacy in the early 1990s established
a restriction of no more than 14.2 prescriptions dispensed per pharmacists per hour.

Preventing Drug Administration Errors:
!
!
!
!
!
!
!
!

Any incomplete, vague or illegible order shall not be carried out until clarified;
No drug should be administered if not properly labelled. During the administration, the labels should
be read three times;
Just prior to administration, the following checks should be performed: the right medication, in the
right dose, to the right patient, by the right route at the right time;
Users should be knowledgeable about the medication administration devices;
Person administering medication should have adequate access to patient information, particularly
allergies, prognosis and treatment plan;
At the time of administration, the name, purpose and the effects of medication should be discussed
with patient/ caregiver;
Patient should be monitored for medication outcome;
The science of ergonomics should be employed in the design of safe system.

Source: Preventing Medication Errors: Strategies for PharmacistJoint Commission Resources

Pharmacist as a Consultant and Team Member
“The usefulness of drug therapy recommendations from a clinical pharmacist is well documented in the
professional literature. One study indicated that family practice physicians in a family medicine clinic
rated 88 percent of pharmacist recommendations as “very useful” and that, 88 percent of patients
improved clinically because of the recommendations.”
Am J Hos Pharm 45:824-827, 1988
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IV to PO Switching - Take it Seriously!
Switching the IV (intravenous) therapy to oral at appropriate time saves a lot, not only in terms of money
but in terms of complications related to IV therapy. Some examples of this could be line/catheter related
infections due to catheter itself or chances of contamination during IV drug preparation . Moreover, better
patient compliance is a very important outcome of this practice.
Many randomised, prospective and interventional studies have quantified the effectiveness of this
programme.
For e.g.:
J Antimicrob Chemother, vol 43, iss 4, p 601-606, yr 1999
This study demonstrates the effectiveness of “switch programme” in a large teaching hospital. The
interesting findings of the study were:
! Therapy was also switched earlier, after a median of 4 days. After completion of the oral course,
recurrence of infections, or readmissions due to reinfections did not occur;
! Compared with the inventorial phase, 43% of IV administrations could be avoided;
! This means a potential annual reduction of dfl.60,000 (c. US$30,000) of administration costs;
! The potential savings in purchase costs of the antibiotics were dfl.54,000 (US$27,000) annually.

Early IV to PO Switch Guidelines:
! Consider drugs with good oral bioavailability;
For e.g. Quinolones (Ciprofloxacin, Levofloxacin, Ofloxacin), Fluconazole, Amoxicillin/Clavulanic acid,
Clindamycin, Clarithromycin, Erythromycin, Cloxacillin, Metronidazole etc.;
! Consider all infective diseases other than severe/life threatening cases of CNS, bone infections,
endocarditis, severe soft tissue infection, abscess, neutropenia, leukopenia and lymphoma etc. ;
! Assess patient for gastrointestinal tolerance (patient taking medicine or food by mouth);
! Consider contraindicated situations like gut surgery, patient not allowed for oral intake, sick patients
on TPN, patients with unreliable gut absorption etc. ;
! Make sure that patient has received at least 48 hours of IV therapy and has shown response to it
(patient is afebrile with normalising total leukocyte count).
Salwa Ahsan (Senior Pharmacist II)

Drug-Drug Interaction Corner
Esomeprazole with Atorvastatin
Outcome: Concurrent use of Atorvastatin and Esomeprazole may result in atorvastatin toxicity including
rhabdomyolysis.
Clinical Management
The concurrent administration of Atorvastatin and Esomeprazole should be approached with caution.
Better to switch the therapy to either Simvastatin + Esomeprazole or Atorvastatin + Omeprazole"
Severity: Major
Documentation: Good
Probable Mechanism:
Esomeprazole inhibition of p-glycoprotein resulting in increased Atorvastatin bioavailability.
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News Alert For Health Care Professionals
FDA Advising of Risk of Birth Defects with Paroxetine
This is to alert health care professionals and patients about early results of new studies for Paroxetine
suggesting that the drug increases the risk for birth defects, particularly heart defects, when women take it
during the first trimester.
Most of the heart defects reported in these studies were atrial and ventricular septal defects. In general,
these types of defects range in severity from those that are minor and may resolve without treatment to
those that cause serious symptoms and may need to be repaired surgically.
Paroxetine is approved for the treatment of depression and several other psychiatric disorders. FDA is
currently gathering additional data and waiting for the final results of the recent studies in order to better
understand the higher risk for birth defects that has been seen with paroxetine.
FDA has asked the manufacturer of Paxil (Paroxetine), Glaxo Smith Kline (GSK), to change the
pregnancy category from C to D, a stronger warning. Category D means that studies in pregnant women
(controlled or observational) have demonstrated a risk to the fetus. However, the benefits of therapy may
outweigh the potential risks to the fetus.
Health care professionals should consider discontinuing paroxetine (and switching to another
antidepressant if indicated) in these patients.
Source: FDA News December 8, 2005

Report Adverse Drug Reactions - This is Important For Patient Safety!
All ADR reports should be submitted to Department of Pharmacy Services in order
for Pharmacy and Therapeutics Committee to review them and
take preventive and corrective measures.
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